Disease · EFO_0010702
Comparisons in its trials63
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 63
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| De Novo Subjects vs Roll-over Subjects: deaths from any cause | 0 of 412 | 0 of 257 | 669 | NCT02510014 | Trial comparisons |
| De Novo Subjects vs Roll-over Subjects: serious adverse events | 16 of 412 | 9 of 257 | 669 | NCT02510014 | Trial comparisons |
| Group 1: SL BPN/NX Tablets + Placebo SC Injections vs Group 2: CAM2038 SC Injections + SL Placebo Tablets: deaths from any cause | 0 of 215 | 1 of 213 | 428 | NCT02651584 | Trial comparisons |
| Group 1: SL BPN/NX Tablets + Placebo SC Injections vs Group 2: CAM2038 SC Injections + SL Placebo Tablets: serious adverse events | 16 of 215 | 5 of 213 | 428 | NCT02651584 | Trial comparisons |
| CAM2038 q1w or q4w With Prior Exposure to SL BPN/NX vs CAM2038 q1w or q4w New to BPN Treatment: deaths from any cause | 0 of 190 | 0 of 37 | 227 | NCT02672111 | Trial comparisons |
| CAM2038 q1w or q4w With Prior Exposure to SL BPN/NX vs CAM2038 q1w or q4w New to BPN Treatment: serious adverse events | 13 of 190 | 2 of 37 | 227 | NCT02672111 | Trial comparisons |
| Before Re-entry vs After Re-entry: deaths from any cause | 1 of 74 | 3 of 72 | 146 | NCT02617628 | Trial comparisons |
| Before Re-entry vs After Re-entry: serious adverse events | 10 of 74 | 13 of 72 | 146 | NCT02617628 | Trial comparisons |
| Extended-release Naltrexone (XR-NTX) vs Treatment as Usual (TAU): deaths from any cause | 2 of 55 | 1 of 59 | 114 | NCT03275350 | Trial comparisons |
| Extended-release Naltrexone (XR-NTX) vs Treatment as Usual (TAU): serious adverse events | 5 of 55 | 7 of 59 | 114 | NCT03275350 | Trial comparisons |
| Extended-release Naltrexone (XR-NTX) vs Treatment as Usual (TAU): Number of Participants With at Least 1 HIV Care Visit in Past 12 Weeks | 31 of 52 | 29 of 58 | 110 | NCT03275350 | Trial comparisons |
| NTX + BUP vs PBO NTX + BUP: Proportion of Subjects Who Receive and Tolerate a VIVITROL Injection on Day 8 | 35 of 51 | 38 of 50 | 101 | NCT02696434 | Trial comparisons |
| NTX + BUP vs PBO NTX + BUP: Incidence of Adverse Events (AEs) | 38 of 50 | 37 of 51 | 101 | NCT02696434 | Trial comparisons |
| NTX + BUP vs PBO NTX + BUP: deaths from any cause | 0 of 50 | 0 of 51 | 101 | NCT02696434 | Trial comparisons |
| NTX + BUP vs PBO NTX + BUP: serious adverse events | 0 of 50 | 1 of 51 | 101 | NCT02696434 | Trial comparisons |
| O-BMT (Onsite Treatment) vs Enhanced Referral: Buprenorphine Diversion | 8 of 48 | 2 of 49 | 97 | NCT03150173 | Trial comparisons |
| O-BMT (Onsite Treatment) vs Enhanced Referral: Buprenorphine Engagement | 19 of 48 | 19 of 49 | 97 | NCT03150173 | Trial comparisons |
| O-BMT (Onsite Treatment) vs Enhanced Referral: Number/Percentage of Participants Who Received Any Buprenorphine Prescription | 36 of 48 | 29 of 49 | 97 | NCT03150173 | Trial comparisons |
| O-BMT (Onsite Treatment) vs Enhanced Referral: Treatment Retention | 2 of 48 | 6 of 49 | 97 | NCT03150173 | Trial comparisons |
| O-BMT (Onsite Treatment) vs Enhanced Referral: deaths from any cause | 0 of 48 | 0 of 49 | 97 | NCT03150173 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0010702/comparisons